101 related articles for article (PubMed ID: 16863922)
21. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I
J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
Guay C; Lépine M; Verreault J; Bénard F
J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411
[TBL] [Abstract][Full Text] [Related]
23. Differentiating recurrent or residual nasopharyngeal carcinomas from post-radiotherapy changes with 18-fluoro-2-deoxyglucose positron emission tomography and thallium-201 single photon emission computed tomography in patients with indeterminate computed tomography findings.
Tsai MH; Huang WS; Tsai JJ; Chen YK; Changlai SP; Kao CH
Anticancer Res; 2003; 23(4):3513-6. PubMed ID: 12926100
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the therapeutic effects and recurrence for head and neck cancer after chemoradiotherapy by FDG-PET.
Hoshikawa H; Mitani T; Nishiyama Y; Yamamoto Y; Ohkawa M; Mori N
Auris Nasus Larynx; 2009 Apr; 36(2):192-8. PubMed ID: 18606510
[TBL] [Abstract][Full Text] [Related]
25. 18F-fluorodeoxyglucose positron emission tomography for predicting tumor response to radiochemotherapy in nasopharyngeal carcinoma.
Su M; Zhao L; Wei H; Lin R; Zhang X; Zou C
Strahlenther Onkol; 2015 Aug; 191(8):642-8. PubMed ID: 25981635
[TBL] [Abstract][Full Text] [Related]
26. [Value of 18F-fluorodeoxyglucose positron emission tomography in three-dimensional conformal radiotherapy for locally persistent or recurrent nasopharyngeal carcinoma].
Ding Y; Wu DH; Chen LH
Di Yi Jun Yi Da Xue Xue Bao; 2005 Dec; 25(12):1568-70. PubMed ID: 16361168
[TBL] [Abstract][Full Text] [Related]
27. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Bares R; Claussen CD; Kanz L; Bokemeyer C
Cancer; 2002 May; 94(9):2353-62. PubMed ID: 12015760
[TBL] [Abstract][Full Text] [Related]
28. Usefulness of (18)F-fluorodeoxyglucose PET for radiosurgery planning and response monitoring in patients with recurrent spinal metastasis.
Gwak HS; Youn SM; Chang U; Lee DH; Cheon GJ; Rhee CH; Kim K; Kim HJ
Minim Invasive Neurosurg; 2006 Jun; 49(3):127-34. PubMed ID: 16921451
[TBL] [Abstract][Full Text] [Related]
29. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
30. Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery.
Kalff V; Duong C; Drummond EG; Matthews JP; Hicks RJ
J Nucl Med; 2006 Jan; 47(1):14-22. PubMed ID: 16391182
[TBL] [Abstract][Full Text] [Related]
31. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas].
Qiao WL; Zhao JH; Wang C; He ZY; Wang TS; Xing Y
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637
[TBL] [Abstract][Full Text] [Related]
32. Metabolic activity on [18f]-fluorodeoxyglucose-positron emission tomography/computed tomography and glucose transporter-1 expression might predict clinical outcomes in patients with limited disease small-cell lung cancer who receive concurrent chemoradiation.
Lee J; Kim JO; Jung CK; Kim YS; Yoo IeR; Choi WH; Jeon EK; Hong SH; Chun SH; Kim SJ; Kim YK; Kang JH
Clin Lung Cancer; 2014 Mar; 15(2):e13-21. PubMed ID: 24368212
[TBL] [Abstract][Full Text] [Related]
33. [Serial (18)F-FDG PET-CT imaging during radiotherapy for nasopharyngeal carcinoma: a prospective clinical study].
Lin Q; Yang RS; Sun L; Li YM; Wang LC; Dai MM; Luo ZM; Zhao L; Wu H
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):356-9. PubMed ID: 22883456
[TBL] [Abstract][Full Text] [Related]
34. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
Pfannenberg AC; Oechsle K; Kollmannsberger C; Dohmen BM; Bokemeyer C; Bares R; Vontheim R; Claussen CD
Rofo; 2004 Jan; 176(1):76-84. PubMed ID: 14712410
[TBL] [Abstract][Full Text] [Related]
35. Detection of recurrent nasopharyngeal carcinomas with positron emission tomography using 18-fluoro-2-deoxyglucose in patients with indeterminate magnetic resonance imaging findings after radiotherapy.
Tsai MH; Shiau YC; Kao CH; Shen YY; Lin CC; Lee CC
J Cancer Res Clin Oncol; 2002 May; 128(5):279-82. PubMed ID: 12029444
[TBL] [Abstract][Full Text] [Related]
36. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
37. Detection and staging of recurrent or metastatic nasopharyngeal carcinoma in the era of FDG PET/MR.
Piao Y; Cao C; Xu Y; Huang S; Jiang F; Jin T; Jin Q; Hua Y; Hu Q; Chen X
Eur Arch Otorhinolaryngol; 2022 Jan; 279(1):353-359. PubMed ID: 33782748
[TBL] [Abstract][Full Text] [Related]
38. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
[TBL] [Abstract][Full Text] [Related]
39. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
[TBL] [Abstract][Full Text] [Related]
40. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
Kitagawa Y; Sano K; Nishizawa S; Nakamura M; Ogasawara T; Sadato N; Yonekura Y
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):63-71. PubMed ID: 12483411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
